ALKS vs. EIDX, AGIO, PCRX, OPK, ALXO, BMRN, NBIX, INCY, UTHR, and RGEN
Should you be buying Alkermes stock or one of its competitors? The main competitors of Alkermes include Eidos Therapeutics (EIDX), Agios Pharmaceuticals (AGIO), Pacira BioSciences (PCRX), OPKO Health (OPK), ALX Oncology (ALXO), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), Incyte (INCY), United Therapeutics (UTHR), and Repligen (RGEN). These companies are all part of the "medical" sector.
Eidos Therapeutics (NASDAQ:EIDX) and Alkermes (NASDAQ:ALKS) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, community ranking, risk, profitability, dividends, media sentiment and valuation.
Eidos Therapeutics has a beta of -0.16, meaning that its share price is 116% less volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500.
In the previous week, Alkermes had 6 more articles in the media than Eidos Therapeutics. MarketBeat recorded 6 mentions for Alkermes and 0 mentions for Eidos Therapeutics. Eidos Therapeutics' average media sentiment score of 1.18 beat Alkermes' score of 0.00 indicating that Alkermes is being referred to more favorably in the news media.
Alkermes has a net margin of 25.17% compared to Alkermes' net margin of 0.00%. Eidos Therapeutics' return on equity of 20.31% beat Alkermes' return on equity.
Alkermes has a consensus price target of $36.78, indicating a potential upside of 53.82%. Given Eidos Therapeutics' higher probable upside, analysts clearly believe Alkermes is more favorable than Eidos Therapeutics.
31.4% of Eidos Therapeutics shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 70.1% of Eidos Therapeutics shares are owned by insiders. Comparatively, 4.9% of Alkermes shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Alkermes received 540 more outperform votes than Eidos Therapeutics when rated by MarketBeat users. Likewise, 70.65% of users gave Alkermes an outperform vote while only 63.20% of users gave Eidos Therapeutics an outperform vote.
Alkermes has higher revenue and earnings than Eidos Therapeutics. Eidos Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.
Summary
Alkermes beats Eidos Therapeutics on 15 of the 17 factors compared between the two stocks.
Get Alkermes News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALKS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALKS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alkermes Competitors List
Related Companies and Tools
